Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

August 7, 2024

Study Completion Date

July 9, 2026

Conditions
Cancer
Interventions
DRUG

SQ3370

SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Trial Locations (10)

2050

RECRUITING

Chris O'Brien Lifehouse, Camperdown

2065

RECRUITING

Royal North Shore Hospital, Sydney

5000

RECRUITING

Cancer Research Institute, Adelaide

63110

RECRUITING

Washington University in St. Louis, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

91010

RECRUITING

City of Hope, Duarte

94304

RECRUITING

Stanford Cancer Center, Palo Alto

97239

RECRUITING

Oregon Health & Science University, Portland

98195

RECRUITING

University of Washington, Seattle

All Listed Sponsors
lead

Shasqi, Inc.

INDUSTRY